[UOADEV] YoY Annualized Quarter Result on 31-Dec-2019 [#4]

Stock
[UOADEV] UOA DEVELOPMENT BERHAD
Announcement Date
26-Feb-2020
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2019
Quarter
31-Dec-2019 [#4]
Profit Trend
QoQ- 4.44%
YoY- 5.43%
Quarter Report
Latest QR
Upcoming QR
UOADEV's Result
UOADEV's Financial Summary
View:
Show?
Annualized Quarter Result
31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 CAGR
Revenue 451,653 547,484 844,597 1,104,457 1,263,677 1,081,602 996,193 -12.34%
PBT 287,213 316,692 479,956 510,097 505,850 656,061 929,364 -17.76%
Tax -64,453 -88,348 -80,223 -101,675 -94,252 -129,283 -218,726 -18.41%
NP 222,760 228,344 399,733 408,422 411,598 526,778 710,638 -17.57%
-
NP to SH 219,937 222,447 391,288 399,474 378,916 491,182 676,726 -17.07%
-
Tax Rate 22.44% 27.90% 16.71% 19.93% 18.63% 19.71% 23.54% -
Total Cost 228,893 319,140 444,864 696,035 852,079 554,824 285,555 -3.61%
-
Net Worth 5,729,729 5,630,046 5,415,616 5,072,339 4,683,094 4,280,790 3,817,347 6.99%
Dividend
31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 CAGR
Div 240,744 232,646 318,565 275,243 258,123 259,967 244,701 -0.27%
Div Payout % 109.46% 104.59% 81.41% 68.90% 68.12% 52.93% 36.16% -
Equity
31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 CAGR
Net Worth 5,729,729 5,630,046 5,415,616 5,072,339 4,683,094 4,280,790 3,817,347 6.99%
NOSH 2,408,583 2,327,599 2,124,905 1,967,157 1,844,871 1,734,247 1,632,469 6.69%
Ratio Analysis
31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 CAGR
NP Margin 49.32% 41.71% 47.33% 36.98% 32.57% 48.70% 71.34% -
ROE 3.84% 3.95% 7.23% 7.88% 8.09% 11.47% 17.73% -
Per Share
31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 CAGR
RPS 18.76 23.53 39.77 56.18 68.54 62.41 61.07 -17.85%
EPS 9.31 10.05 19.34 21.07 21.26 29.26 43.07 -22.52%
DPS 10.00 10.00 15.00 14.00 14.00 15.00 15.00 -6.53%
NAPS 2.38 2.42 2.55 2.58 2.54 2.47 2.34 0.28%
Adjusted Per Share Value based on latest NOSH - 1,967,157
31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 CAGR
RPS 18.13 21.97 33.90 44.33 50.72 43.41 39.98 -12.34%
EPS 8.83 8.93 15.70 16.03 15.21 19.71 27.16 -17.07%
DPS 9.66 9.34 12.79 11.05 10.36 10.43 9.82 -0.27%
NAPS 2.2997 2.2597 2.1736 2.0358 1.8796 1.7181 1.5321 7.00%
Price Multiplier on Financial Quarter End Date
31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 CAGR
Date 30/12/22 31/12/21 31/12/20 31/12/19 31/12/18 29/12/17 30/12/16 -
Price 1.61 1.67 1.69 2.03 2.12 2.39 2.35 -
P/RPS 8.58 7.10 4.25 3.61 3.09 3.83 3.85 14.28%
P/EPS 17.62 17.47 9.17 9.99 10.32 8.43 5.67 20.79%
EY 5.67 5.73 10.90 10.01 9.69 11.86 17.65 -17.23%
DY 6.21 5.99 8.88 6.90 6.60 6.28 6.38 -0.44%
P/NAPS 0.68 0.69 0.66 0.79 0.83 0.97 1.00 -6.22%
Price Multiplier on Announcement Date
31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 CAGR
Date 22/02/23 24/02/22 24/02/21 26/02/20 05/03/19 21/02/18 22/02/17 -
Price 1.66 1.70 1.70 1.98 2.22 2.54 2.50 -
P/RPS 8.85 7.22 4.27 3.52 3.24 4.07 4.09 13.72%
P/EPS 18.17 17.78 9.23 9.74 10.80 8.96 6.03 20.17%
EY 5.50 5.62 10.84 10.26 9.26 11.16 16.59 -16.80%
DY 6.02 5.88 8.82 7.07 6.31 5.91 6.00 0.05%
P/NAPS 0.70 0.70 0.67 0.77 0.87 1.03 1.07 -6.82%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment